"Corporate Communications for oncology product and technology companies should go beyond traditional investor relations to include synthesis of key pre and clinical information, insight into the development strategy and timing, the target patient population, and the clinical attributes of a new product relative to existing standards of care. John does this better than anyone we know. He has the technical oncology expertise the functional expertise, and the relationships that really matter to support both brand and corporate objectives. Think twice before going elsewhere."